UNSPSC 51182211: Epostane

This classification denotes an anti-progestin with the molecular formula C22H31NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6375T36951, chemically known as 4,17-dimethyltrilostane but generally known as epostane, which bears US NIH Compound Identifier 51331. European Medicines Agency schedules Epostane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06582MIG. The term EPOSTANE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24).

UNSPSC 51182211 Epostane, a Commodity code, covers generic multi-source pharmaceuticals and over-the-counter products that state and local government facilities procure through cooperative purchasing agreements and direct solicitations. State and local buyers under this code include state departments of administration and health, counties, cities, school districts, and other public facilities that source drugs and OTC products for employee health plans, correctional systems, mental-health facilities, and general administrative use. Procurement bodies typically issue RFPs to establish blanket or master agreements with manufacturers and pharmaceutical distributors, requiring compliance with current Good Manufacturing Practices (cGMP), Drug Supply Chain Security Act (DSCSA) certification, FDA requirements, and supply-chain security protocols including network security and privacy liability coverage. Vendors must maintain relationships with authorized wholesalers and accommodate multiple pricing models including flat price, net price formats (NF30, NF60, NF90), and WAC-minus structures to serve the diverse purchasing needs of participating jurisdictions.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted a Request for Proposal on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products serving Minnesota and Oregon participating facilities. MMCAP requires vendors to supply through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with products available by May 15, 2026 and awarded contracts effective July 1, 2026. Evaluation emphasizes price competitiveness (75 percent weight), fixed pricing stability (10 percent), EDI capability (5 percent), administrative compliance (5 percent), and agreement to a 3 percent administrative fee (5 percent), with performance penalties of $200 to $1,500 per violation for late reporting, missed onboarding, or improper class-of-trade denials. No specific dollar ceiling or set-aside designations are disclosed; contract terms run two years for new vendors with optional extensions, or align existing agreements through June 30, 2028 for incumbents.